

PM-TW-MPL-PPTX-250114

Date of Preparation: August 2025

Trademarks are owned by or licensed to the GSK group of companies

GSK address: 100台北市忠孝西路一段66號23樓

藥物不良反應可通報至葛蘭素史克藥廠

電話: (02) 23126836/ 信箱: oax40892@gsk.com

Intended for Taiwan Healthcare Professionals Only

Achieving remission with Mepolizumab in EGPA

部立桃園醫院
風濕免疫過敏科
曾國森醫師



Summary



Symptoms of EGPA vary between patients and can be life-threatening^{1–3}

Eosinophils are a key driver in EGPA¹



Current treatments involve oral corticosteroids and immunosuppressive agents⁴

Patients on long-term steroids can experience significant complications⁵



Nucala is the only approved anti-IL-5 with proven efficacy in EGPA⁶

Nucala reduced blood eosinophils to normal healthy levels^{7*}

Patients on Nucala reduced their symptoms and steroid dose burden⁷

Nucala had a safety profile similar to placebo⁸

*Normal healthy levels: 30–395 eosinophils/ μ L (5th–95th percentile), from LEAD study: longitudinal, observational, population-based Austrian cohort. General population that had eosinophil count measured: n=11,042. Healthy sub-population: n=3,641. Geometric mean value within the healthy sub-population: 107 eosinophils/ μ L (95% CI: 105–110).⁹

References: 1. Baldini C *et al. Rheum Dis Clin North Am.* 2010;36(3):527–543. 2. Gioffredi A *et al. Front Immunol.* 2014;5:549. 3. National Institutes of Health. Genetic and Rare Diseases Information Center. April 2018. Eosinophilic granulomatosis with polyangiitis. Available at: <https://rarediseases.info.nih.gov/diseases/6111/eosinophilic-granulomatosis-with-polyangiitis>. (Accessed: April 2021). 4. Groh M *et al. Eur J Int Med* 2015;26(7):545–53. 5. Price DB *et al. Journal of Asthma and Allergy* 2018;11 193–204. 6. Nucala SmPC; August 2020. 7. Wechsler ME *et al. N Engl J Med.* 2017;376:1921–1932.(Supplementary data). 8. Wechsler ME *et al. N Engl J Med.* 2017;376:1921–1932. 9. Hartl S *et al. Eur Respir J.* 2020;55(5).